The entire focus is to see whether or not patent laws have been violated and if less expensive generics were in any way stalled from getting to the market place. It all boils down to intellectual-property rights and patient disputes. Interesting that Teva is settling lawsuits and will be supplying medications before the patents expire. It appears if you pay enough in a court case or fine, the door opens to begin selling the generic versions. Allegra has been one such drug in the news of late with a settlement of this type. BD
Teva Pharmaceutical Industries Ltd., the world's biggest generic-drug maker, France's Les Laboratoires Servier and Slovenia's Krka Group d.d. have been raided by European Union regulators as part of an antitrust investigation. The raids of the three drugmakers on Monday came as the European Commission is scheduled to release a report this Friday in Brussels on possible antitrust abuses in the pharmaceutical industry. The commission began that probe in January after raiding offices of GlaxoSmithKline Plc, AstraZeneca Plc, Sanofi- Aventis SA and several competitors. The EU's review of the pharmaceutical industry is focused on whether research-based companies misuse patent rules and lawsuit settlements to keep less-expensive generics off the market.
Spokesmen for Glaxo, Europe's largest drugmaker, Novartis AG, Sanofi, Merck KGaA, Novo Nordisk A/S, Boehringer Ingelheim, and AstraZeneca said they weren't aware of this week's raids.
Hat Tip: Pharmagossip